LJUIF (SSY Group) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LJUIF SSY Group Ltd LJUIF
86 GF Score
Price $0.40
GF Value $0.51
! 8 Warning Signs
View Full Analysis

What is SSY Group FFO?

FFO (Funds from operations) only applies to REITs.

LJUIF
86GF Score
SSY Group Ltd LJUIF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SSY Group (LJUIF) Overvalued in 2026?

Based on GuruFocus' analysis, SSY Group stock appears to be undervalued. The current stock price of $0.40 is trading 21.1% below its estimated GF Value™ of $0.51.

Key valuation signals for LJUIF:

  • FFO:
  • GF Value™: $0.51 vs. price of $0.40 (21.1% below fair value)
  • GF Score™: 86/100 with 8 warning signs

No single metric tells the full story. See the LJUIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SSY Group Business Description

Other Exchanges 02005:Hong Kong
Address Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score

Get the complete analysis for LJUIF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price
$0.51
GF Value